Margaret Macro - Concepedia

Author

Margaret Macro

Centre Hospitalier Universitaire de Caen Normandie ORCID

Also Known As

M Macro, M. MACRO, M. Macro, Macro, Margaret, Margaret MACRO, Margaret Macro, Pascal Lenain

257

Publications

13.3K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Caen Normandie Sorbonne Université Université de Caen Normandie Hôpital Saint-Louis Inserm

About

Margaret Macro is an author at Centre Hospitalier Universitaire de Caen Normandie specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	30	2.9K
2	Health Sciences	14	17	2.4K
3	Cell Biology	3	3	63
4	Biostatistics	1	1	29
5	Blood Transplantation	1	1	52

Margaret Macro

Publications

12.3K

Citations

H-Index

Page 1

	Year	Citations
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste, Blood	2010	1.5K
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin, New England Journal of Medicine	2017	1.2K
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Thierry Façon, Shaji Kumar, Torben Plesner, New England Journal of Medicine	2019	947
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Philippe Moreau, Michel Attal, Cyrille Hulin, The Lancet Hematological MalignancyRadiation OncologyMedicineImmunologyHematology	2019	922
High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial Jean‐Paul Fermand, Philippe Ravaud, Sylvie Chevret, Blood	1998	539
Treatment of Older Patients with Mantle-Cell Lymphoma Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine, New England Journal of Medicine	2012	511
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Journal of Clinical Oncology	2010	419
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre, Blood	2018	408
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe Jean‐Paul Fermand, Sandrine Katsahian, Marine Diviné, Journal of Clinical Oncology	2005	400
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial Thierry Façon, Shaji Kumar, Torben Plesner, The Lancet Oncology Hematological MalignancyDexamethasone Versus LenalidomideMedicineHematologyMyeloid Neoplasia	2021	345

Page 1